Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05621811 · ClinicalTrials.gov registry record · Phase 2
Different Doses of Naronapride Vs. Placebo in Gastroparesis
A Phase 2 study of Gastroparesis, sponsored by Dr. Falk Pharma.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 320
- Enrollment target
- 20
- Study locations
NCT05621811: Recruiting Phase 2 study of Gastroparesis, sponsored by Dr. Falk Pharma.
NCT05621811 is a Phase 2 study of Gastroparesis that is actively recruiting participants, run by Dr. Falk Pharma. The registered enrollment target is 320 participants, roughly in line with the 295-participant average among 44 other Gastroparesis trials with a reported enrollment target. The trial reports 20 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05621811, a Phase 2 study of Gastroparesis, is actively recruiting participants, sponsored by Dr. Falk Pharma.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 320 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a double-blind, randomized, multicenter, placebo-controlled, comparative phase II dose-finding trial. The trial will be conducted with four treatment groups in the form of a parallel group comparison and will serve to compare oral treatment with daily doses of 10, 20, or 40 mg Naronapride vs. placebo for the treatment of patients with Gastroparesis.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Naronapride
Study Locations (20)
Florida
- Dr Falk Investigational Site - Clearwater
- Dr Falk Investigational Site - Doral
- Dr Falk Investigational Site - Hollywood
- Dr Falk Investigational Site - Maitland
- Dr Falk Investigational Site - Miami
- Dr Falk Investigational Site - Miami
- Dr Falk Investigational Site - Viera
California
- Dr Falk Investigational Site - Chula Vista
- Dr Falk Investigational Site - Lomita
Louisiana
- Dr Falk Investigational Site - Houma
- Dr Falk Investigational Site - Marrero
Michigan
- Dr Falk Investigational Site - Flint
- Dr Falk Investigational Site - Flint
Tennessee
- Dr Falk Investigational Site - Cordova
- Dr Falk Investigational Site - Nashville
Kansas
- Dr Falk Investigational Site - Topeka
Kentucky
- Dr Falk Investigational Site - Crestview Hills
New York
- Dr Falk Investigational Site - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 320 participants |
| Start Date | 2023-01-03 |
| Est. Completion | 2025-12 |
| Phase | Phase 2 |
What NCT05621811 shows while recruiting
NCT05621811 is an interventional study that assigns participants to a tested intervention. The registered 320 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 295-participant average among 44 other Gastroparesis trials with a reported enrollment target.
The record links to 1 condition, with Gastroparesis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05621811 names 20 study sites across 10 states, led by Florida, California, Louisiana.
Frequently Asked Questions
What is clinical trial NCT05621811 about?
NCT05621811 is a clinical study titled "Different Doses of Naronapride Vs. Placebo in Gastroparesis". This is a double-blind, randomized, multicenter, placebo-controlled, comparative phase II dose-finding trial. The trial will be conducted with four treatment groups in the form of a parallel group comparison and will serve to compare oral treatment with daily doses of 10, 20, or 40 mg Naronapride vs...
What is the current status of trial NCT05621811?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 320 participants. The study started on 2023-01-03. Estimated completion is 2025-12.
What conditions does trial NCT05621811 study?
This clinical trial studies the following conditions: Gastroparesis.
What interventions are being tested in trial NCT05621811?
The interventions under investigation include: Placebo (DRUG), Naronapride (DRUG).
Who is sponsoring clinical trial NCT05621811?
This trial is sponsored by Dr. Falk Pharma, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05621811 being conducted?
This trial has 20 study locations across California, Florida, Kansas, Kentucky, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gastroparesis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05621811's enrollment target sits among peer trials
320 6th of 44 higher than 39 of 44 other Gastroparesis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Gastroparesis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Dose Response of 28 Days of Dosing of GSK962040 in Type I and II Diabetic Male and Female Subjects With Gastroparesis
COMPLETED · Phase 2
-
Study to Assess the Efficacy of VLY-686 in Relieving Symptoms of Gastroparesis
COMPLETED · Phase 2
-
Gastroparesis Registry 4
RECRUITING
-
The Use of Body Surface Gastric Mapping in Assessing the Clinical Success of G-POEM
RECRUITING · NA
-
Study of Gastric Motility in Eosinophilic Gastritis
RECRUITING
-
Indiana University Gastrointestinal Motility Diagnosis Registry
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02763683 · 320 participants
Investigations of Dementia in Parkinson Disease
- NCT03331198 · 320 participants · Phase 1
Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
- NCT03458832 · 320 participants
Clinical Trial Readiness to Solve Barriers to Drug Development in FSHD
- NCT03551951 · 320 participants
Tumor Cell and DNA Detection in the Blood, Urine, and Bone Marrow
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI